Serum vaspin may be a good indicator of fibrosis in chronic hepatitis C and is not altered by antiviral therapy

Kukla, Michał; Waluga, Marek; Sawczyn, Tomas; Berdowska, Agnieszka; Kajor, Maciej; Boryczka, Grzegorz; Stygar, Dominika; Gabriel, Andrzej; Żwirska-Korczala, K; Hartleb, Marek

doi:10.5114/pjp.2012.32767

Cited by 17 publications

(22 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, there was no difference in vaspin serum levels between patients with different stages of cirrhosis according to Child-Pugh and MELD scores. This is in accordance with previous results showing that there is no further increase in vaspin serum levels when advanced fibrosis appears[21,22]. …”

Section: Discussionsupporting

confidence: 94%

“…The current study for the first time compared serum vaspin levels in cirrhotic patients with and without PVT and did not find any difference between these groups. Our previous study in CHC patients suggested serum vaspin to be a potential predictor of advanced liver fibrosis, with evident increases in subjects with advanced fibrosis[21]. However, in patients with insignificant fibrosis, serum vaspin level were significantly lower than in controls.…”

Section: Discussionmentioning

confidence: 98%

“…Serum levels of vaspin in CHC patients without fibrosis or with less advanced fibrosis were significantly lower than in healthy controls. However, in patients with bridging fibrosis or cirrhosis, the levels were almost as high as in the control group[21,22]. In NAFLD patients, vaspin serum levels seemed to be higher in patients with definite NASH and more advanced fibrosis[23,24].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum omentin and vaspin levels in cirrhotic patients with and without portal vein thrombosis

Kukla

Waluga

Żorniak

et al. 2017

WJG

Self Cite

View full text Add to dashboard Cite

AIMTo investigate serum omentin and vaspin levels in cirrhotic patients; and to assess the relationship of these levels with hemostatic parameters, metabolic abnormalities, cirrhosis severity and etiology.METHODSFifty-one cirrhotic patients (17 with portal vein thrombosis) were analyzed. Serum omentin and vaspin levels were measured with commercially available direct enzyme-linked immunosorbent assays (ELISAs). To assess platelet activity, the following tests were performed using a MULTIPLATE®PLATELET FUNCTION ANALYZER: (1) an ADP-induced platelet activation test; (2) a cyclooxygenase dependent aggregation test (ASPI test); (3) a von Willebrand factor and glycoprotein Ib-dependent aggregation (using ristocetin) test (RISTO test); and (4) a test for thrombin receptor-activating peptide-6 induced activation of the thrombin receptor, which is sensitive to IIb/IIIa receptor antagonists.RESULTSOmentin, but not vaspin, serum concentrations were significantly decreased in patients with portal vein thrombosis (PVT) (P = 0.01). Prothrombin levels were significantly increased in patients with PVT (P = 0.01). The thrombin receptor activating peptide (TRAP) test results were significantly lower in the PVT group (P = 0.03). No significant differences in adipokines serum levels were found regarding the etiology or severity of liver cirrhosis assessed according to the Child-Pugh or Model of End-Stage Liver Disease (MELD) scores. There was a significant increase in the TRAP (P = 0.03), ASPI (P = 0.001) and RISTO high-test (P = 0.02) results in patients with lower MELD scores. Serum omentin and vaspin levels were significantly down-regulated in patients without insulin resistance (P = 0.03, P = 0.02, respectively). A positive relationship between omentin and vaspin levels were found both when all of the patients were analyzed (r = 0.41, P = 0.01) and among those with PVT (r = 0.94, P < 0.001).CONCLUSIONSerum omentin levels are increased in patients without PVT. Cirrhosis origin and grade do not affect omentin and vaspin levels. The analyzed adipokines do not influence platelet activity.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Discussionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum omentin and vaspin levels in cirrhotic patients with and without portal vein thrombosis

Kukla

Waluga

Żorniak

et al. 2017

WJG

Self Cite

View full text Add to dashboard Cite

show abstract

“…Moreover, IR is a strong predictor of poor response to antiviral therapy, alongside advanced hepatic steatosis and fibrosis [6,14]. Numerous reports have demonstrated altered levels of some adipokines such as leptin, adiponectin, resistin, visfatin, vaspin, chemerin and fibroblast growth factor (FGF) 21 in CHC patients [4,15,16,17,18,19,20].…”

Section: Introductionmentioning

confidence: 99%

Omentin serum concentration and hepatic expression in chronic hepatitis C patients – together or apart?

Kukla¹,

Waluga²,

Adamek³

et al. 2015

pjp

Self Cite

View full text Add to dashboard Cite

Chronic hepatitis C (CHC) is accompanied by numerous metabolic disorders, partially associated with altered adipokine system regulation. Omentin (intelectin-1) is a novel adipokine known to play a pivotal role in metabolic regulation in CHC. In a group of 63 CHC patients (29 men/34 women) infected with genotype 1b, aged 6.6 ±14.6 years, serum omentin levels and its gene expression in liver tissue were examined and their association with metabolic and histopathological features was assessed. Serum omentin levels were significantly higher in CHC patients compared to controls (p < 0.001), regardless of sex, body mass index (BMI), insulin sensitivity and lipid concentrations. There was no correlation between serum omentin and omentin hepatic expression. Neither parameter was associated with any histological features. Serum omentin in non-obese CHC patients seems not to be related to metabolic disorders or liver pathology. Omentin hepatic expression shows no relationship with either serum omentin levels or histopathological features. This suggests different mechanisms regulating circulating omentin concentration and omentin hepatic expression in CHC.

show abstract

“…Nonetheless, in patients without fibrosis and with insignificant fibrosis vaspin serum levels were significantly lower. An evident increase invaspinlevelswasobservedinpatientswithatleast periportalfibrosis(stage2),withnofurtherincrease inpatientswithadvancedfibrosis.Thenextintriguing aspect was the fact that serum vaspin levels in patientswithadvancedfibrosiswassimilartothosein thecontrolgroup [33].Althoughitsimproperclearancebyimpairedliveror/andacompensatoryincrease havingaprotectiveeffectdirectedagainstfurtherliver injury and fibrosis progression could be possible explanations, a potential negative action of vaspin when NAFLD progresses to more advanced stages withfibrosismaynotbeexcluded.Thispresumption is based on the fact that vaspin inhibits expression of profibrogenic factors such as leptin, TNF-α, and resistin [21].Nevertheless,whenfibrosiswasestablished vaspin serum levels were not associated with itsseverityassessedaccordingChild-PughandModel ofEnd-StageLiverDisease(MELD)scores [34].Itis wellknownthatIRisanimportantriskfactoroffibrosisprogressioninchronicliverdiseases,including NAFLD [4,12,35,36,37].Inourstudy,HOMA-IR was significantly associated with fibrosis stage supportingearlierfindings.Inthecurrentstudy,hepatic vaspinmRNAexpressionwashigherinpatientswith fibrosis,butthedifferencedidnotreachstatisticalsignificance.Unfortunately,significantfibrosis(stage2) was observed only in 16% of patients. Moreover, therewerenopatientswithbridgingfibrosisorcirrhosis.Thissmallnumberofpatientswithsignificant and the lack of those with advanced fibrosis in our groupmayinfluencetheobtainedresults.…”

Section: Discussionmentioning

confidence: 99%

Vaspin mRNA levels in the liver of morbidly obese women with nonalcoholic fatty liver disease

Waluga¹,

Kukla²,

Żorniak³

et al. 2017

pjp

Self Cite

View full text Add to dashboard Cite

Serum vaspin may be a good indicator of fibrosis in chronic hepatitis C and is not altered by antiviral therapy

Cited by 17 publications

References 26 publications

Serum omentin and vaspin levels in cirrhotic patients with and without portal vein thrombosis

Serum omentin and vaspin levels in cirrhotic patients with and without portal vein thrombosis

Omentin serum concentration and hepatic expression in chronic hepatitis C patients – together or apart?

Vaspin mRNA levels in the liver of morbidly obese women with nonalcoholic fatty liver disease

Contact Info

Product

Resources

About